Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM:SONN Stock Report

Market Cap: US$4.8m

Sonnet BioTherapeutics Holdings Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Pankaj Mohan

Chief executive officer

US$626.6k

Total compensation

CEO salary percentage86.0%
CEO tenure10yrs
CEO ownership0.5%
Management average tenure5.2yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

CEO Compensation Analysis

How has Pankaj Mohan's remuneration changed compared to Sonnet BioTherapeutics Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024US$627kUS$539k

-US$7m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023n/an/a

-US$14m

Sep 30 2023US$635kUS$539k

-US$19m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022n/an/a

-US$29m

Sep 30 2022US$1mUS$560k

-US$30m

Jun 30 2022n/an/a

-US$29m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021n/an/a

-US$25m

Sep 30 2021US$792kUS$512k

-US$25m

Jun 30 2021n/an/a

-US$67m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020n/an/a

-US$69m

Sep 30 2020US$2mUS$490k

-US$66m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019n/an/a

-US$7m

Sep 30 2019US$548kUS$368k

-US$5m

Compensation vs Market: Pankaj's total compensation ($USD626.63K) is about average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Pankaj's compensation has been consistent with company performance over the past year.

CEO

Pankaj Mohan (59 yo)

10yrs

Tenure

US$626,626

Compensation

Dr. Pankaj Mohan, Ph.D. founded Sonnet BioTherapeutics Holdings, Inc. in 2015 and has since served as a member of its Board of Directors. Dr. Mohan has been Chairman of Sonnet BioTherapeutics Holdings, Inc...

Leadership Team

NamePositionTenureCompensationOwnership
Pankaj Mohan
Founder10yrsUS$626.63k0.51%
$ 24.6k
John Cini
Chief Scientific Officer & Co-Founder10yrsUS$419.66k0.070%
$ 3.4k
Jay Cross
Chief Financial Officer5.7yrsUS$406.81k0.053%
$ 2.5k
Donald Griffith
Financial Controller & Director6yrsUS$93.94k0.012%
$ 600.0
Gael Hedou
Chief Operating Officerno datano datano data
Susan Dexter
Chief Technical Officer4.8yrsno data0.0063%
$ 305.6
Richard Kenney
Chief Medical Officer3.8yrsno datano data
Manuel Dafonseca
Head of Clinical Operations3.8yrsno datano data
Stephen McAndrew
Senior Vice President of Business Developmentless than a yearno datano data

5.2yrs

Average Tenure

67.5yo

Average Age

Experienced Management: SONN's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pankaj Mohan
Founder10yrsUS$626.63k0.51%
$ 24.6k
Donald Griffith
Financial Controller & Director9.8yrsUS$93.94k0.012%
$ 600.0
Hossein Borghaei
Member of Scientific Advisory Boardno datano datano data
Lori McNeill
Independent Director2.3yrsUS$64.33k0.013%
$ 630.4
Albert Dyrness
Independent Director5.3yrsUS$59.83k0.018%
$ 859.4
Nailesh Bhatt
Independent Director6.5yrsUS$58.33k0.018%
$ 875.3
Guido Cavaletti
Member of Scientific Advisory Boardno datano datano data
Raghu Rao
Independent Director5.2yrsUS$120.83k0.078%
$ 3.8k
Jason Bock
Member of Scientific Advisory Boardno datano datano data
Robert Wenham
Member of Scientific Advisory Board2.3yrsno datano data

5.3yrs

Average Tenure

60yo

Average Age

Experienced Board: SONN's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 21:46
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sonnet BioTherapeutics Holdings, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Michael KingH.C. Wainwright & Co.